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Abstract
Background: Tumor-associated macrophages (TAMs) are abundant in gliomas and immunosuppressive TAMs are a
barrier to emerging immunotherapies. It is unknown to what extent macrophages derived from peripheral blood
adopt the phenotype of brain-resident microglia in pre-treatment gliomas. The relative proportions of blood-derived
macrophages and microglia have been poorly quantified in clinical samples due to a paucity of markers that
distinguish these cell types in malignant tissue.
Results: We perform single-cell RNA-sequencing of human gliomas and identify phenotypic differences in
TAMs of distinct lineages. We isolate TAMs from patient biopsies and compare them with macrophages from
non-malignant human tissue, glioma atlases, and murine glioma models. We present a novel signature that
distinguishes TAMs by ontogeny in human gliomas. Blood-derived TAMs upregulate immunosuppressive cytokines and
show an altered metabolism compared to microglial TAMs. They are also enriched in perivascular and necrotic regions.
The gene signature of blood-derived TAMs, but not microglial TAMs, correlates with significantly inferior survival
in low-grade glioma. Surprisingly, TAMs frequently co-express canonical pro-inflammatory (M1) and alternatively
activated (M2) genes in individual cells.
Conclusions: We conclude that blood-derived TAMs significantly infiltrate pre-treatment gliomas, to a degree
that varies by glioma subtype and tumor compartment. Blood-derived TAMs do not universally conform to the
phenotype of microglia, but preferentially express immunosuppressive cytokines and show an altered metabolism. Our
results argue against status quo therapeutic strategies that target TAMs indiscriminately and in favor of
strategies that specifically target immunosuppressive blood-derived TAMs.
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Background
The cellular heterogeneity of tumor-associated macro-
phages (TAMs) is a critical roadblock to the development
of cancer immunotherapies. For example, macrophage
colony-stimulating factor, a hematopoietic growth factor
that promotes macrophage survival, is over-expressed in
glioma. Murine gliomas can be regressed by inhibiting
colony-stimulating factor receptor (CSF1R) [1]. However,
clinical trials targeting CSF1R have so far failed to increase
overall survival [2]. Evidence suggests that subpopulations
of TAMs are resistant to CSF1R inhibition [3]. Another
example is acquired resistance to the anti-angiogenesis
therapy bevacizumab. Here, blood-derived TAMs prefer-
entially contribute to therapy resistance, relative to brain-
resident microglia [4]. Thus, TAM heterogeneity is a
barrier to effective immunotherapies. Moreover, CSF1R
blockade exemplifies the status quo, which seeks to target
TAMs indiscriminately even though TAMs can play both
tumor-supportive and anti-tumor roles.
In glioma, TAMs comprise two populations: brain-
resident microglia, whose progenitors migrate to the
central nervous system (CNS) during early development
[5]; and macrophages that differentiate from bone
marrow-derived monocytes, that have extravasated the
blood–brain barrier [6]. Studies of the differences be-
tween these two populations have been confounded by a
lack of specific markers to separately purify these cell
types from human gliomas [7]. How ontogeny contrib-
utes to TAM education in the glioma microenvironment
is not fully understood.
There have been mixed reports of the degree to which
bone marrow-derived macrophages (BMDM) contribute
to the TAM pool in murine gliomas. Irradiation followed
by a transfer of labeled bone marrow was used to show
that the majority of TAMs are brain-resident microglia
[8]. On the other hand, macrophage lineage-tracing,
using a genetic system that does not involve irradiation,
demonstrated that BMDM do infiltrate murine gliomas
to a significant extent [9]. It is unclear to what extent
BMDMs infiltrate untreated human gliomas. It is un-
known whether BMDMs adopt the phenotype of brain-
resident microglia in malignant conditions.
To address this, we applied single-cell RNA-sequencing
(scRNA-seq) to pre-treatment human gliomas. We com-
pared gene expression in TAMs to microglia and macro-
phages, derived from non-malignant human tissue. We
integrated our scRNA-seq with published glioma cohorts
and lineage tracing studies in mouse. We correlated TAM
composition with glioma molecular subtype and overall
survival. Using public glioma atlases, we mapped TAM
signatures to tumor anatomical structures and identified
recurrent regional variation in TAM composition.
We found that human TAMs in vivo exhibit both
canonical and non-canonical activation states, yet
express durable markers of lineage. We present novel gene
signatures that are specific to human TAMs of bone mar-
row and microglial origin, respectively. Blood-derived
TAMs significantly infiltrate pre-treatment gliomas. Their
infiltration correlates with tumor grade and varies by gli-
oma subtype. Compared to TAMs of microglial origin,
blood-derived TAMs upregulate immunosuppressive cyto-
kines and markers of an oxidative metabolism, character-
istic of the M2 phenotype. Blood-derived TAMs aggregate
in perivascular and necrotic regions, compared to micro-
glia. Elevated expression of blood-derived-TAM markers,
but not microglial-TAM marker genes, correlates with
significantly inferior overall survival in grade II–III low-
grade glioma (LGG). Taken together, these results support
targeting immunosuppressive TAMs derived from periph-
eral blood and therapies that normalize the blood–brain
barrier.
Results
Single-cell sequencing produces a transcriptome-wide
assessment of TAM expression patterns in vivo
We endeavored to assess both inter- and intra-tumor TAM
heterogeneity, by assembling a cohort that spanned glioma
grades and molecular subtypes. We profiled TAMs from
patient biopsies, derived from 13 untreated primary gliomas
(11 glioblastomas [GBMs], two LGGs; Additional file 1:
Table S1), and combined this with public data from an add-
itional 580 glioma cases. We performed scRNA-seq on
seven of the in-house cases (five GBMs, two LGGs)
[10, 11]. ScRNA-seq data were available from 12 pub-
lished LGG cases [12, 13].
To robustly assess the in-house cases, we applied two
orthogonal scRNA-seq platforms: the Fluidigm C1
(which produces full-transcript coverage); and the 10X
Genomics platform (which produces 3’ tagged data, but
at a higher cellular throughput). We performed C1-
based scRNA-seq for three primary GBMs and one pri-
mary grade 3 oligodendroglioma. Additionally, we used
10X-based scRNA-seq to profile two primary GBMs and
one primary grade 2 astrocytoma.
To increase the number of TAMs profiled, we addition-
ally purified TAMs from four of the cases (two GBMs,
one G3 oligo., one G2 astro.), using the canonical macro-
phage marker CD11b (see “Methods” and Fig. 1a). We
validated our isolation protocol via flow cytometry,
and the purity of CD11b-expressing cells was over
96% (Additional file 2: Figure S1a). For these cases,
we separately performed scRNA-seq on both a whole-
tumor suspension and a CD11b-purified suspension.
We next sought to purify TAMs in silico from the
whole-tumor scRNA-seq. Additionally, we wanted to fil-
ter any non-TAMs that were inadvertently sequenced in
the CD11b-purified scRNA-seq. We took separate
approaches for the C1 and 10X data.
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We obtained 672 cells from the C1-based scRNA-seq.
We removed 206 cells with low sequencing depth and/
or low transcript diversity [14]. We then separated
scRNA-seq libraries based on two techniques: (1) clus-
tering by gene expression; and (2) analysis of clonal,
somatic mutations identified in matched exome-
sequencing (exome-seq) data (see “Methods”). To com-
pare expressed mutations between exome-seq and
scRNA-seq data, we used our previously described
methodology [15, 16].
We found that putative TAMs identified from the
whole-tumor scRNA-seq clustered together with TAMs
sequenced from the CD11b + suspensions and away
from putative neoplastic cells from the whole-tumor
scRNA-seq. Both t-distributed stochastic neighbor em-
bedding (tSNE) and hierarchical clustering in a space of
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Fig. 1 ScRNA-seq of neoplastic and immune cells from human primary gliomas. a Both whole-tumor and CD11b-purified single-cell suspensions,
derived from glioma biopsies, were subjected to scRNA-seq (top) allowing for quantification of markers in single cells from both populations (bot-
tom). b t-distributed stochastic neighbor embedding plot of cells from whole-tumor and CD11b-purified scRNA-seq, colored by the presence of
somatic mutations that are clonal in exome sequencing (top) or by the expression of canonical marker genes (bottom), measured in counts per
million (CPM). c Hierarchical clustering of cells (columns), grouped by their expression of canonical marker genes (rows)
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canonical markers show a clear separation between neo-
plastic and TAM populations (Fig. 1b, c). Putative TAMs
are devoid of expressed somatic mutations, but robustly
express class II human-leukocyte antigen and other
macrophage-specific genes. On the other hand, puta-
tive neoplastic cells express somatic mutations identi-
fied as clonal in exome-seq and express high levels of
receptor-tyrosine kinases. For all downstream analysis
of TAMs from the C1 platform, we exclusively used
those cells (n = 142) that robustly expressed TAM
markers and were devoid of somatic mutations.
For the 10X data, we initially filtered non-TAMs from the
CD11b-purified scRNA-seq, based on the expression of ca-
nonical macrophage markers (Additional file 2: Figure S1b).
In agreement with our CD11b-purity assessments via flow
cytometry, 91% of cells (n = 907) were identified as TAMs.
We then performed transcriptional clustering of the TAMs
from the CD11b-purified scRNA-seq, together with cells
from the whole-tumor 10X-based scRNA-seq. This identi-
fied an additional 3132 TAMs, which clustered together
with TAMs from the CD11b-purified 10X-based
scRNA-seq and robustly expressed canonical macro-
phage markers (Additional file 2: Figure S1c). To test
for potential batch effects, we compared two inde-
pendent 10x captures (Additional file 2: Figure S1d)
from the same tumor sample (SF11136). The cells
aggregated in run-independent clusters, pointing to
limited technical variance introduced by single-cell
capture and sequencing.
Lastly, we retrieved published data from scRNA-seq of
TAMs from nine astrocytomas (n = 1039 cells) and three
oligodendrogliomas (n = 235 cells) [12, 13]. The identity of
these cells had been previously determined by Venteicher
et al. based on an absence of somatic mutations, and the
expression of macrophage markers [17], which we
confirmed (Additional file 2: Figure S1e). The final
scRNA-seq dataset used for all subsequent analysis com-
prises 5455 TAMs (1274 published cells and 4181 novel
cells) from 19 patients.
A gene signature that distinguishes TAMs by ontogeny in
mice is conserved in human glioma
Lineage tracing and RNA sequencing (RNA-seq) has
been used to isolate and profile BMDM and microglia
from murine glioma models [9]. Bowman et al. used
both irradiation-based and genetic lineage-tracing
systems. They found 836 genes that were differentially
expressed between BMDM and microglial TAMs, recur-
rently in both models (Additional file 3: Table S2). We
reasoned that these genes would contain a core signa-
ture of lineage identity that might be conserved in hu-
man. We compared homologues of these murine TAM
genes to genes expressed in human macrophages.
We found that 237 of the lineage-specific murine-TAM
genes had homologues that were expressed in human
TAMs (Fig. 2a). On the other hand, 565 of the lineage-
specific mouse genes were expressed by human macro-
phages of some ontogeny [18–21], in non-malignant con-
ditions. On average, genes that are differentially expressed
in mouse are also differentially expressed between human
BMDM and microglia from non-malignant tissue (Fig. 2b).
However, this agreement is not universally the case,
underscoring the need to compare murine models with
studies of human clinical samples.
To resolve whether the 237 mouse homologues are
sufficient to identify discrete subpopulations of human
TAMs, we performed principal component analysis
(PCA) in the space of those genes using our scRNA-seq
data (Additional file 2: Figure S2a). Gaussian mixture
modeling of the resulting sample scores, along principal
a
237
565
732
836
−
4
−
2
0
2
4
Genes enriched 
in murine 
blood-derived
TAMs
Genes enriched 
in murine
microglial TAMs
Lo
g2
 fo
ld
-c
ha
ng
e
hu
m
an
 n
on
-m
al
ig
na
nt
 
B
M
D
M
s/
M
ic
ro
gl
ia
b
p<1e-16
Differenially expressed in murine TAMs
Homologue in human
Expressed in non-malignant human macrophages/microglia
Expressed in human TAMs
Fig. 2 Analysis of published data identifies markers of ontogeny. a The intersection of: (1) genes that are differentially expressed between blood-
derived and microglial TAMs in mouse (outer circle); (2) their homologues; (3) genes expressed (mean CPM > 1) in human BMDM/microglia from
non-malignant tissue; and (4) TAMs from human gliomas (n = 16 patients). b Distributions of the log2 ratios (human BMDMs over microglia) (y-
axis) for the differentially expressed murine-TAM homologues from (a)
Müller et al. Genome Biology  (2017) 18:234 Page 4 of 14
component 1 (PC1), showed two distinct subpopulations.
To determine the utility of combining the C1 and Smart-
seq2 datasets, we performed multiple factor analysis
(MFA), a generalization of PCA used to combine multiple
tables of measurements (Additional file 2: Figure S2b). We
found that the per table contributions to variance
explained from each of the datasets were approximately
equal (ratio of partial inertias = 0.832).
In a PCA of the combined table, we found that PC1
stratified TAMs into two distinct platform-independent
populations (Fig. 3a, Additional file 2: Figure S2a). The
intersection of these two clusters, as estimated by a
Gaussian mixture model, is < 5%. A consensus clustering
of TAMs in the space of the 237 homologues recapitu-
lates the clustering identified via PCA (Matthew’s correl-
ation 0.946, Fig. 3b). Markers of murine microglial
TAMs are enriched in genes that negatively load PC1,
while makers of murine blood-derived TAMs are
enriched in genes that positively load PC1 (Fisher’s exact
test p < 1e-4). Thus, genes differentially expressed
between murine TAM lineages also distinguish two pop-
ulations in human gliomas.
We identified 66 genes that strongly loaded PC1
(Fig. 3c, Additional file 2: Figure S3c, Additional file 4:
Table S3, Additional file 5: Table S4), which were differ-
entially expressed between blood-derived and murine
microglial TAMs (Fig. 3d), and which were tightly corre-
lated across human gliomas in RNA-seq data from The
Cancer Genome Atlas (TCGA) (Fig. 3e, Additional file 2:
Figure S3a) [22]. A PCA of the 10X-derived scRNA-seq,
also using the same set of 237 homologues, validated
our expression signature. Here, too, PC1 identifies two
populations, distinguished by the expression of our core
signature genes (Additional file 2: Figure S3b). We
propose these 66 genes (Additional file 5: Table S4) as
core markers of lineage, as they are differentially
expressed between microglial and blood-derived macro-
phages, in human and in mouse, in malignant and in
non-malignant tissue.
CX3CR1 is widely used to isolate murine microglia in
both non-malignant [23] and malignant conditions [24].
In human tissue, however, it is known that CX3CR1 is
expressed by monocytes and its expression increases
during differentiation into macrophages; thus, isolation
of human microglial TAMs via CX3CR1 alone may rep-
resent an enrichment more than a purification [24–26].
On the other hand, P2RY12 came up in all of our
analyses as a specific marker of microglial TAMs. Also,
P2RY12 is known to be specific to microglia vs bone-
marrow macrophages in non-malignant tissues [27, 28].
To determine if P2RY12 was expressed by human
microglial TAMs at the protein level, we performed
multicolor flow cytometry for CD11b, P2RY12, and
CX3CR1 on leukocytes isolated from a human GBM-
biopsy (SF10941). We found three distinct populations of
TAMs (Fig. 3f, top left). One population of CD11b + cells
is P2RY12- and CX3CR1- (putative CX3CR1- BMDM),
one CD11b + population is CX3CR1+ and P2RY12- (puta-
tive CX3CR1+ BMDM), and one population is CD11b
+/CX3CR1+/P2RY12+ (putative microglia).
We also stained for HLA-DRA in SF10941, a core
component of class II human-leukocyte antigen, which
our scRNA-seq data predicted was enriched in blood-
derived TAMs relative to microglia. We found that
P2RY12+ microglia express intermediate HLA-DR levels,
while P2RY12– macrophages are characterized by high
HLA-DR levels (Fig. 3f, top right). Additionally, we per-
formed analytical flow cytometry on a GBM biopsy from
an additional patient (SF11425), staining for CD11b,
P2RY12, and the blood-derived macrophage marker
CD49D (encoded by ITGA4). We found two main popu-
lations of CD11b + cells: P2RY12+ CD49D– cells and
CD49D+ P2RY12– cells, underlining the ability of these
two markers to distinguish macrophages and microglia
on the protein level (Fig. 3f, bottom).
TAMs of distinct ontogenies are enriched in distinct
tumor-anatomical structures
We quantified our TAM-lineage signature in data from
the Ivy Glioblastoma Atlas Project (IGAP) [29]. IGAP re-
searchers have performed RNA-seq on microdissections
of specific glioma anatomical structures, identified from
hematoxylin and eosin (H&E) staining. Gene markers of
human microglial TAMs are enriched in samples from the
leading edge of invading gliomas and in adjacent infil-
trated white matter. Genes specific to blood-derived
TAMs are localized in regions of hyperplastic blood ves-
sels, microvascular proliferation, and in peri-necrotic
regions (Fig. 3g, Additional file 2: Figure S3d).
Additionally, we assessed in situ hybridizations for
TGFBI and BIN1 in glioma tissue sections from IGAP.
These two genes are lineage markers for macrophages
and microglia, respectively, from our 66-gene signature.
As predicted, we found enrichment of TFGBI near puta-
tive blood vessels. Moreover, BIN1 is enriched in infil-
trated white matter and its expression decreases rapidly
in the cellular tumor (Fig. 3h).
TAMs of distinct ontogenies express distinct gene
programs
We found that our lineage signature also separates
brain-derived perivascular macrophages from microglia,
in scRNA-seq data from mouse [30] and human [31]
non-malignant cortex (Fig. 4). Like our blood-derived
TAMs, these perivascular macrophages arose from per-
ipheral monocytes that permeated the blood–brain
barrier [30]. Consistent with this common lineage, both
human blood-derived TAMs and murine perivascular
Müller et al. Genome Biology  (2017) 18:234 Page 5 of 14
a b
e
c
−1
−0.8
−0.6
−0.4
−0.2
0
0.2
0.4
0.6
0.8
1T
G
F
B
I
IT
G
A
4
F
P
R
3
K
Y
N
U
IF
IT
M
2
S
10
0A
11
N
A
V
3
S
LC
1A
3
S
IG
LE
C
8
P
2R
Y
12
C
X
3C
R
1
TGFBI
ITGA4
FPR3
KYNU
IFITM2
S100A11
NAV3
SLC1A3
SIGLEC8
P2RY12
CX3CR1
PCC
P2
ry1
2
Sl
c1
A3
Na
v3
Si
gle
ch
Ifit
m
2
Fp
r2
Tg
fb
i
Ky
nu
S1
00
a1
1
-10
-5
0
5
Lo
g2
 F
C
 m
ou
se
 
M
ac
ro
ph
ag
e 
vs
 M
ic
ro
gl
ia
 T
A
M
s
* * *
*
* * *
* *
Itg
a4
*
PC1
0.5
0
D
en
si
ty
Putative blood-derived TAMPutative microglial TAM
−2 −1 0 1 2 3
−
4
−
3
−
2
−
1
0
1
2
P
C
2
d
P2RY12
CX3CR1
NAV3
SIGLEC8
SLC1A3
TGFBI
IFITM2
FPR3
S100A11
KYNU
ITGA4
-1 10
z-score
PC1
TAMs
f
g
Le
ad
ing
 ed
ge
Inf
iltr
ati
ng
 tu
mo
r
Ce
llul
ar 
tum
or
Pe
rin
ec
rot
ic z
on
e
Hy
pe
rpl
as
tic
blo
od
 ve
sse
ls
Mi
cro
va
scu
lar
pro
life
rat
ion
Ps
eu
do
pa
lisa
din
g 
ce
lls
FPR3
ITGA4
TGFBI
KYNU
S100A11
IFITM2
SLC1A3
CX3CR1
P2RY12
SIGLEC8
NAV3
-1 10
z-score
1
S
im
ilarity
Putative
blood-derived
TAMs
Putative
microglial
TAMs
Putative microglial TAM based on PCA
Putative blood-derived TAM based on PCA
1
0
BIN1 (Microglial TAM marker) TGFBI (Blood-derived TAM marker)
Hyperplastic blood vessels
Infiltrating tumor
Cellular tumor
Leading edge
Blood vesselLeading edge/
infiltrating tumor
Cellular tumor Necrotic region
h
Inter-
mediate
High
24.1 %
5.84 %55.0 %
15.1 %
10
1
10
2
10
3
10
4
10
5
Qdot 705-A :: CD49D (ITGA4)
10
1
10
2
10
3
10
4
10
5
F
IT
C
-A
 ::
 P
2R
Y
12
40.3 % 2.51 %
0.30 %56.9 %
0-103 103 10
4
105
FITC-A :: P2RY12
0
-10
3
10
3
10
4
10
5
P
E
-C
y7
-A
 ::
 C
X
3C
R
1
69.3 % 2.78 %
0 %27.9 %
0-103 103 10
4
105
FITC-A :: P2RY12
0
-10
3
10
3
10
4
105
P
er
C
P
-C
y5
-5
-A
 ::
 H
LA
-D
R
Fig. 3 (See legend on next page.)
Müller et al. Genome Biology  (2017) 18:234 Page 6 of 14
macrophages express a common gene signature. In our
data, both cell types upregulate the phagocytic receptor
CD93, relative to microglia. This is in accord with the
known role of perivascular macrophages as constitutive
phagocytes [32, 33]. Likewise, mouse and human microglia
from non-malignant brain share a signature of their lineage
that is conserved in microglial TAMs (Additional file 6:
Table S5), including P2RY12.
A differential-expression test between human blood-
derived and microglial TAMs (DESeq adj. p value < 1e-3)
confirmed a phagocytic phenotype in blood-derived TAMs.
Blood-derived TAMs upregulate numerous structural
components of the phagolysosome and a variety of
phagocytosis-promoting receptors (Additional file 2:
Figure S4a), compared to microglial TAMs. Intri-
guingly, blood-derived TAMs express significantly
higher levels of genes typically associated with an im-
munosuppressive, alternatively activated (M2) pheno-
type, such as IL10 and TGFB2, compared to microglia
(Additional file 7: Table S6).
An activated tricarboxylic acid (TCA) cycle is a hall-
mark of M2 macrophage metabolism. Conversely, in
classically activated (M1) macrophages, the TCA cycle is
broken in two places: after citrate production and again
after succinate production [34, 35]. Blood-derived TAMs
show significantly elevated levels of genes that are rate-
limiting for citrate and succinate processing at exactly
these two breakpoints (Additional file 2: Figure S4b).
This suggests an activation of the TCA cycle in in
blood-derived TAMs.
The gene signature for blood-derived TAMs varies by
glioma subtype and correlates with significantly shorter
overall survival in LGG
We calculated scores for blood-derived and microglial-
TAM signature genes by averaging gene sets in glioma
RNA-seq data from TCGA (n = 558). It is well-known
that the degree of macrophage infiltration in glioma cor-
relates with tumor grade [36]. However, this conclusion
is based on studies that do not distinguish between mac-
rophages of different lineages. Our data show a signifi-
cant increase in blood-derived TAMs, but not in
microglial TAMs, in GBM compared to LGG (Fig. 5a).
In fact, astrocytomas have a degree of microglia infiltra-
tion, which is significantly higher than oligodendrogli-
omas or even GBMs (Tukey’s range test p < 0.01).
Survival analysis, corrected for age and gender, revealed
that the signature of blood-derived TAMs correlates with
significantly shorter survival in LGG (p = 0.016, haz-
ard ratio [HR] = 3.44). However, there is no correl-
ation between survival and the microglial-TAM
signature (Fig. 5b). A similar correlation between
blood-derived TAMs and survival is present in GBM
(Additional file 2: Figure S5), although it is not
significant at the 5% level (p = 0.109, HR = 1.61).
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Fig. 4 Markers of ontogeny from human TAMs also separate
brain-derived perivascular macrophages from microglia in
scRNA-seq of mouse and human non-malignant cortex. A PCA of
human TAMs (orange/pink, n = 1416 cells), human microglia from
non-malignant cortex (purple, n = 17 cells), murine microglia from
non-malignant cortex (blue, n = 33 cells), and murine perivascular
macrophages from non-malignant cortex (red, n = 65 cells). PCA
was performed in the space of 87 genes that are differentially
expressed between murine-TAM lineages and robustly measured
across all datasets (mean CPM > 1 in all datasets)
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Fig. 3 A gene signature to separate TAMs by ontogeny in mouse and human gliomas. a PCA of human TAMs in the space of genes that are
ontogeny-specific in murine gliomas. The density curves of a Gaussian mixture model are in gray. b Consensus clustering of TAMs in the space of
genes that are ontogeny-specific in murine gliomas. PCA-based cluster assignments from (a) are indicated by color. c Heatmap of the average ex-
pression (z-score) of indicated genes in windows of ten cells, sorted according to their PC1 score. d Log2 ratios of gene expression in murine
blood-derived TAMs over murine microglial TAMs, averaged over the mouse models of Bowman et al. * = adjusted p value < 0.05 in both mouse
models. Error bars indicate standard error of the mean. e Pearson correlation coefficients, computed via RNA-seq of LGGs and GBMs from TCGA
(n = 558 cases). Genes are ordered by hierarchical clustering, boxes indicate a dendogram cut obtaining two clusters. f Top left: Flow cytometric
analysis of TAMs gated on live CD11b +myeloid cells from a primary GBM (SF10941) stained for P2RY12 and CX3CR1. Top right: Flow cytometric
analysis of TAMs gated on live CD11b +myeloid cells from a primary GBM (SF10941) stained for P2RY12 and HLA-DR. Bottom: Flow cytometric
analysis of TAMs gated on live CD11b +myeloid cells from a primary GBM (SF11425) stained for P2RY12 and CD49D (encoded by ITGA4). g Gene
expression from the Ivy Glioblastoma Atlas Project. Each column annotates expression in RNA‐seq of an anatomically defined tumor compartment. h In
situ hybridization for BIN1 and TGFBI in anatomically annotated regions (indicated by color) for two primary GBMs
Müller et al. Genome Biology  (2017) 18:234 Page 7 of 14
A significant fraction of TAMs co-express canonical
markers of M1 and M2 activation in individual cells
As noted, we observed an increased expression of
IL10, TGFB2, and genes associated with an oxidative
metabolism in blood-derived TAMs, relative to micro-
glia (Additional file 7: Table S6). These are all
markers of macrophage M2 activation. Unexpectedly,
however, we also found that individual TAMs fre-
quently co-expressed canonical markers of both M1
and M2 activation (Fig. 6a–c). For example, in our
C1-based scRNA-seq data, 66% of TAMs that express
the M2 marker IL10 also express the M1 marker
TNF-α. We observed these non-canonical states in
our TAM data from all three platforms, as well as in
published scRNA-seq of TAMs derived from human
melanoma samples (Additional file 2: Figure S6a)
[37].
To further evaluate co-expression of M1 and M2
genes at the protein level, we performed analytical flow
cytometry for CD11b, the M1 marker CD86, and the M2
marker CD206 (encoded by MRC1) in a GBM patient
biopsy (SF11448). Consistent with our analysis on the
messenger RNA (mRNA) level, we found a significant
fraction of TAMs co-expressing these markers (Fig. 6d).
To determine if these non-canonical states were
restricted to a lineage, we then performed analytical flow
cytometry on three additional GBM patient biopsies
(PITT001, PITT002, PITT003). In addition to CD11b,
P2RY12, and CD49D, we stained for TLR2 (a canonical
M1 marker) and CD204 (encoded by MSR1, an M2
marker). In agreement with our scRNA-seq data, we
found that the M1 and M2 markers were frequently co-
expressed in individual CD11b + cells (Fig. 6e). Both
P2RY12+ microglial TAMs and CD49D+ blood-
derived TAMs demonstrated non-canonical states
(Fig. 6f, Additional file 2: Figure S6b).
Discussion
Our primary finding is that while blood-derived TAMs
do significantly infiltrate pre-treatment human gliomas,
they do not adopt the phenotype or regional distribution
of microglial TAMs. Compared to microglia, blood-
derived TAMs upregulate immunosuppressive cytokines,
markers of active phagocytosis, and markers of an acti-
vated TCA cycle. To derive this result, we performed
scRNA-seq of clinical glioma specimen. This uniquely
enabled us to quantify differences between subpopula-
tions of TAMs, in vivo. Our scRNA-seq identified a
novel gene signature that distinguishes blood-derived
macrophages from microglia in both malignant and
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non-malignant conditions. We mapped this signature to
RNA-seq of microdissections from defined glioma ana-
tomical structures. From that mapping, we show that
microglia are enriched in the leading edge of tumor infil-
tration, while blood-derived TAMs are enriched near
blood vessels and necrotic foci. The gene signature of
blood-derived TAMs significantly and negatively corre-
lates with survival in LGG, but the microglial-TAM sig-
nature does not. Collectively, these results support
the idea that there are durable gene markers of
macrophage lineage and that macrophage ontogeny is
critical to shaping macrophage activation in the gli-
oma microenvironment.
CX3CR1 is frequently used to identify microglia in
tumor specimen [24]. However, we and others have found
that purinergic receptors (e.g. P2RY12) are more specific
than CX3CR1, as markers of microglial TAMs [9, 16, 17].
We present here a comprehensive list of markers to isolate
TAMs by ontogeny, from human and mouse gliomas.
Venteicher et al. observed clear signatures for micro-
glial and blood-derived macrophages in a PCA of TAMs
from LGG. In addition, they found a continuum of inter-
mediate transcriptional programs, rather than a bimodal
distribution [17]. Two factors enabled us to develop a
66-gene signature, which separates TAMs by ontogeny
in both malignant (Fig. 3a, Additional file 2: Figure S3b)
and non-malignant (Fig. 4) tissues, both in human and
in mouse (Fig. 4).
First, it is well-known that there is more macrophage
infiltration in GBM compared to LGG. Our analyses
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support this being due to increased BMDM induction
(Fig. 5a). Consistent with this, < 20% of the 1274 TAMs
sequenced in Venteicher et al.’s study of LGG were
BMDM, by our estimates. The TAMs we sequenced in
this study are primarily from GBMs and approximately
70% of the 4181 novel TAMs profiled are BMDM. Thus,
the combination dataset provides a comprehensive sam-
pling of TAMs from both ontogenies and across glioma
grades.
Second, the results of the murine lineage tracing ex-
periments of Bowman et al. [9] were critically import-
ant as a basis for feature selection, before blood-derived
vs microglial TAM classification. There is only a 5%
overlap in a Gaussian mixture model of PC1 scores
(Fig. 3a), using these genes. Moreover, the lineage-
specific genes we identified tightly correlate by on-
togeny and anti-correlate between ontogenies, across
single cells (Fig. 3a, b), across the glioma population in
both LGG and GBM cases (Fig. 3e), and across tumor
regions (Fig. 3g). Thus, we conclude that this 66-gene
signature distinguishes macrophages by ontogeny in
both human and murine tissues, in both malignant and
non-malignant conditions (Fig. 4).
Historically, macrophage activation has been classified
into either a pro-inflammatory M1 state or an M2 state
associated with the resolution of inflammation [38]. A
more recent scRNA-seq study, in a mouse model of
CNS injury, showed that macrophages can simultan-
eously express markers of both M1 and M2 activation
[39]. Transcriptomic profiling of TAMs has shown lim-
ited overlap between TAM expression signatures and
canonical M1/M2 expression profiles [40]. Furthermore,
there are reports of M1 markers both positively [41] and
negatively [24] correlating with glioma growth. In our
data, individual TAMs co-express canonical markers of
M1 and M2 activation with significant frequency, which
may help explain these conflicting findings.
One limitation of our study is that expression at the
protein level may not reflect expression at the mRNA
level for all of our lineage markers derived from scRNA-
seq. While we have validated several lineage markers at
the protein level, which combination of these markers
will be optimal for isolating TAMs by ontogeny, pro-
spectively from human gliomas, is yet to be determined.
Moreover, in this study we found that blood-derived
TAMs adopt phenotypes that are distinct from those
adopted by brain-resident microglia. Additional func-
tional studies will be required to determine the mecha-
nisms by which differences in ontogeny contribute to
macrophage activation toward M1 or M2.
Conclusion
There is mounting evidence that systemic immune acti-
vation is required for an optimal anti-tumor response
[42]. To what extent peripheral BMDM contribute to
the TAM pool and how macrophage ontogeny shapes
macrophage activation is therefore of critical importance
to the development of immunotherapies. We used
scRNA-seq, combined with public data meta-analysis, to
show that blood-derived and microglial TAMs exhibit
distinct phenotypes and distinct localizations within the
tumor. Blood-derived TAMs upregulate M2-associated
immunosuppressive cytokines and markers of an oxida-
tive metabolism that are characteristic of the M2 pheno-
type. These results argue against status quo approaches
which target both lineages equally and in favor of strat-
egies to specifically deplete the immunosuppressive
blood-derived fraction. To the best of our knowledge,
this work represents the first application of scRNA-seq
to GBM-derived myeloid cells. Both the data and results
presented here will enable future studies of the effect of
therapy on the immune response, by contributing to our
baseline knowledge of innate immunity in untreated
glioma.
Methods
Tumor tissue acquisition and processing
We acquired fresh tumor tissue from patients undergoing
surgical resection for glioma. De-identified samples were
provided by the Neurosurgery Tissue Bank at the
University of California San Francisco (UCSF). Sample use
was approved by the Institutional Review Board at UCSF.
The experiments performed here conform to the princi-
ples set out in the WMA Declaration of Helsinki and the
Department of Health and Human Services Belmont
Report. All patients provided informed written consent.
Tissues were minced in collection media (Leibovitz’s L-15
medium, 4 mg/mL glucose, 100 u/mL Penicillin, 100 ug/
mL Streptomycin) with a scalpel. Samples dissociation
was carried out in a mixture of papain (Worthington
Biochem. Corp) and 2000 units/mL of DNase I freshly
diluted in EBSS and incubated at 37 °C for 30 min. After
centrifugation (5 min at 300 g), the suspension was resus-
pended in PBS. Subsequently, suspensions were triturated
by pipetting up and down ten times and then passed
through a 70-μm strainer cap (BD Falcon). Last, centrifu-
gation was performed for 5 min at 300 g. After resuspen-
sion in PBS, pellets were passed through a 40-μm strainer
cap (BD Falcon), followed by centrifugation for 5 min at
300 g. The dissociated, single cells were then resuspended
in GNS (Neurocult NS-A (Stem Cell Tech.), 2 mM L-Glu-
tamine, 100 U/mL Penicillin, 100 ug/mL Streptomycin,
N2/B27 supplement (Invitrogen), sodium pyruvate).
CD11b + cell isolation
In total, 20 μL of CD11b microbeads (Miltenyi Biotec;
130-093-634) were mixed with the 80 μL single-cell sus-
pension (produced as above) in PBS supplemented with
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2 μM EDTA and 0.5% bovine serum albumin (BSA)
(MACS buffer) and incubated at 4 °C for 15 min. Cells
were washed twice with MACs buffer, centrifuged for
10 min at 300 g, and resuspended in MACs buffer. The
suspension was then applied to a MACS LS column in
the magnetic field of a MACS Separator. Columns were
washed three times with MACs buffer and magnetically
labeled cells were then flushed into a collection tube.
The purity of CD11b + cells was assessed via flow cytom-
etry: CD11b + and CD11b– fractions were staining with
phycoerythrin-conjugated anti-CD11b (Clone M1/70)
antibody for 15 min; cells were then washed twice and
analyzed on a FACsCaliber flow cytometer using FACS-
DIVA software (Additional file 2: Figure S1a).
Single-cell RNA sequencing
Fluidigm C1-based scRNA-seq
Fluidigm C1 Single-Cell Integrated Fluidic Circuit (IFC)
and SMARTer Ultra Low RNA Kit were used for single-
cell capture and complementary DNA (cDNA) gener-
ation. cDNA quantification was performed using Agilent
High Sensitivity DNA Kits and diluted to 0.15–0.30 ng/
μL. The Nextera XT DNA Library Prep Kit (Illumina)
was used for dual indexing and amplification with the
Fluidigm C1 protocol. Ninety-six scRNA-seq libraries
were generated from each tumor/Cd11b + sample and
subsequently pooled for 96-plex sequencing. cDNA was
purification and size selection was carried out twice
using 0.9X volume of Agencourt AMPure XP beads
(Beckman Coulter). The resulting cDNA libraries were
quantified using High Sensitivity DNA Kits (Agilent).
10X genomics-based scRNA-seq
Tissue was dissociated by incubation in papain with 10%
DNAse for 30 min. A single-cell suspension was ob-
tained by manual trituration using a glass pipette. The
cells were filtered via an ovomucoid gradient to remove
debris, pelleted, and resuspended in Neural Basal Media
with serum at a concentration of 1700 cells/uL. In total,
10.2 uL of cells were loaded into each well of a 10X
Chromium Single Cell capture chip and a total of two
lanes were captured. Single-cell capture, reverse tran-
scription, cell lysis, and library preparation were per-
formed per manufacturer’s protocol.
Sequencing for both platforms was performed on a
HiSeq 2500 (Illumina, 100-bp paired-end protocol).
Exome-sequencing and genomic mutation identification
The NimbleGen SeqCap EZ Human Exome Kit v3.0
(Roche) was used for exome capture on a tumor sample
and a blood control sample from each patient. Samples
were sequenced with an Illumina-HiSeq 2500 machine
(100-bp paired-end reads). Reads were mapped to the
human grch37 genome with BWA [43] and only
uniquely matched paired reads were used for analysis.
PicardTools (http://broadinstitute.github.io/picard/) and
the GATK toolkit [44] carried out quality score re-
calibration, duplicate-removal, and re-alignment around
indels. Large-scale (>100 Exons) somatic copy number
variants (CNVs) were inferred with ADTex [45]. To in-
crease CNV size, proximal (< 1 Mbp) CNVs were
merged. Somatic SNVs were inferred with MuTect
(https://www.broadinstitute.org/cancer/cga/mutect) for
each tumor/control pair and annotated with the Anno-
var software package [46].
Single-cell RNA-sequencing data processing and
neoplastic-cell classification
Data processing was performed as described previously
[14]. Briefly, reads were quality trimmed and Trim-
Galore! (http://www.bioinformatics.babraham.ac.uk/pro-
jects/trim_galore/) clipped Nextera adapters. HISAT2
[47] was used to perform alignments to the grch37 hu-
man genome. Gene expression was quantified using the
ENSEMBL reference with featureCounts [48]. Only cor-
rectly paired, uniquely mapped reads were kept. In each
cell, expression values were scaled to counts per million
(CPM). Low-quality cells were filtered by thresholding
number of genes detected at 800 and at least 50,000
uniquely aligned reads. tSNE plots visualizing groupings
of cells were carried out using the Seurat R package [49].
CNVs that were called in matched exome-seq data were
quantified in individual cells as previously described
[15]. Briefly, megabase-scale CNVs were identified in
tumor/normal paired exome-seq datasets, and then
quantified in individual cells using a control sample from
non-malignant brain.
Public data acquisition
Expression matrices from bulk RNA-seq (performed in
triplicate) were downloaded from GEO for the following
samples: representing BMDM, we obtained M0
(GSE68482) [50], M1, M2 macrophages (GSE36952)
[51], and monocytes (GSE58310) [52]. We also obtained
data for microglia purified from epilepsy-related surgical
specimen (n = 3) and post-mortem brain (n = 5)
(GSE80338) [53]. Lists of genes that are differentially
expressed between blood-derived murine TAMs and
microglial murine TAMs, in two murine glioma models,
were downloaded [9]. Normalized scRNA-seq counts
were obtained from GEO for astrocytoma (GSE89567)
and oligodendroglioma (GSE70630). Analysis was re-
stricted to TAMs, as classified in the BROAD single-cell
data portal (https://portals.broadinstitute.org/single_cell).
Normalized counts from TCGA RNA-seq data were
obtained from the Genomics Data Commons portal
(https://gdc.cancer.gov/). Patients diagnosed as GBM
and wild-type IDH1 expression (n = 144) as well as those
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with LGG classification and IDH1 mutation (n = 414), as
given in [54], were normalized to log2(CPM + 1) and
used for analysis. Z-score normalized counts from re-
gional RNA-seq of 122 samples from ten patients was
obtained via the web interface of the IVY GAP
(http://glioblastoma.alleninstitute.org/) database. Fur-
thermore, images of in situ RNA hybridizations in
glioma tissue sections were downloaded for two pa-
tients: BIN1: W11-1-1-E.1.04, 57-year-old man, glio-
blastoma; TGFBI: W8-1-1-B.1.04, 49-year-old woman,
glioblastoma.
Derivation of ontogeny-specific expression signatures
Genes differentially expressed between blood-derived
TAMs and microglial TAMs, recurrently in both of
Bowman et al.’s two murine glioma models, were used
as a starting point [9]. We identified homologues of
these differentially expressed mouse genes with the bio-
maRt package in R [55]. The resulting set of genes was
filtered for genes expressed in our human-TAM scRNA-
seq data. Genes with a mean expression > 1 CPM were
retained. This set of genes was used as the basis for sub-
sequent PCA and single-cell consensus clustering (SC3).
Expression values, defined as log2 (CPM/10 + 1), of
genes in the human-TAM scRNA-seq data were z-score
normalized, across cells from within each single-cell
platform (SMARTer vs SMART-Seq2) independently.
Subsequently, PCA followed by Varimax rotation was
performed. Sample scores, along PC1, were partitioned
using a two-component Gaussian mixture model. Genes
strongly associated with PC1 in either direction were
identified by applying a threshold of abs(loading) > 0.2 to
the gene loadings. MFA was performed on the Smart-
Seq2 and C1 data, using the FactoMineR (https://cran.r-
project.org/web/packages/FactoMineR/index.html) R
package, using the 237 mouse homologue genes. Genes
strongly loading PC1 in the PCA were compared to
RNA-seq data from microdissections of defined glioma
anatomical structures, via the IVY atlas (http://glio-
blastoma.alleninstitute.org/), and visualized with mor-
pheus (https://software.broadinstitute.org/morpheus/).
SC3 clustering [56] (k = 2) was also performed in the
human-TAM scRNA-seq data, restricted to the set of
human counterparts of lineage-specific murine-TAM
genes. Both classifiers produced highly similar classifica-
tion results (Matthews correlation coefficient = 0.946). To
identify genes significantly co-occurring in single cells, we
calculated the odds ratios (OR) and p values as described
in [57]. P values were corrected for multiple testing with
Benjamini–Hochberg.
Calculation of ontogeny scores and survival analysis
For each sample in the TCGA dataset (described above)
we calculated the average expression of microglial-TAM
genes and blood-derived TAM genes, respectively. To
compare the relative amount of infiltration between gli-
oma subtypes, we utilized the glioVis portal [58] to clas-
sify isocitrate dehydrogenase 1/2 (IDH1/2) wild-type
GBM samples into three transcriptional subtypes: Clas-
sical; Mesenchymal; and Proneural. IDH1/2-mutant
LGGs were subdivided into astrocytomas (n = 110) and
oligodendrogliomas (n = 117) based on histology and the
presence/absence of a 1p/19p co-deletion.
For both the microglial and blood-derived TAM sur-
vival analysis, Progene V2 was used. High- and low-
expression cohorts were defined as cases with expression
scores above and below the median score, respectively.
GBMs and LGGs were considered separately. We ad-
justed for age and gender by adding these covariates to a
cox proportional hazards model [59].
Analytical flow cytometry
De-identified fresh glioma tissues were obtained as de-
scribed above, in “Tumor tissue acquisition and process-
ing.” Tissue was mechanically dissociated, resuspended
in 70% Percoll (Sigma-Aldrich), overlaid with 37% and
30% Percoll, and centrifuged for 20 min at 500 × g.
Enriched leukocyte populations (TIL) were recovered at
the 70–37% interface, washed twice in PBS, and resus-
pended in flow staining buffer (PBS + 1% BSA) contain-
ing Human TruStain FcX (Biolegend). Cells were then
incubated at 4° for 30 min with antibodies, washed twice
in flow staining buffer, and analyzed on a BD FACSAria
cell sorter.
The following antibodies were purchased from Biole-
gend: FITC anti-mouse/human CD282; PE anti-human
P2RY12; PE/Cy7 anti-human CD204; APC/Fire™ 750
anti-mouse/human CD11b; APC anti-human CD49d;
PerCP/Cy5.5 anti-human HLA-DR; and BV421 anti-
human CD206. All antibodies were used according to
the manufacturers’ recommended usage.
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